ABSTRACT
INTRODUCTION
Effective screening for fetal trisomies 21, 18 and 13 can be provided at 11-13 weeks' gestation by assessment of a combination of maternal age, fetal nuchal translucency thickness (NT), fetal heart rate (FHR) and maternal serum free β-human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein-A (PAPP-A). In a previous study, we used data from prospective screening in 56 954 singleton pregnancies between July 1999 and February 2006 to develop an algorithm for the calculation of patient-specific risks for trisomy 21, 18 and 13 1 . First, the maternal age-related risk for each trisomy at term was calculated and adjusted according to the gestational age at the time of screening [2] [3] [4] . Second, the measured NT was transformed into a likelihood ratio for each trisomy, using the mixture model of NT distributions; in both trisomic and unaffected pregnancies, fetal NT follows two distributions, one in which NT increases with fetal crown-rump length (CRL dependent) and another which is CRL independent 5 . Third, the measured free β-hCG and PAPP-A were converted into multiples of the median (MoM) for gestational age, adjusted for maternal weight, ethnicity, smoking status, method of conception, parity and machine used for the assays 6, 7 . Fourth, the measured FHR was adjusted for gestational age and delta values were calculated as deviations from the expected normal mean 1 . Fifth, trivariate Gaussian distributions were fitted to the joint distribution of delta FHR, log free β-hCG MoM and log PAPP-A MoM in normal pregnancies and those with trisomy 21, 18 and 13. Sixth, the likelihood ratios for NT, FHR and for the biochemical markers were multiplied with the age-related odds at the time of screening in each case. Seventh, detection rates (DR) and false-positive rates (FPR) were calculated by taking the proportion with risks above a given risk threshold after adjustment for maternal age according to the distribution of pregnancies in England and Wales in 2000-2002 8 . It was estimated that such combined screening would be associated with a DR of 91%, 97% and 94% for trisomy 21, 18 and 13, respectively, at an overall FPR of 3.1% 1 . The objective of this study was to report the accuracy of the first-trimester combined test in screening for trisomies 21, 18 and 13 in 108 982 prospectively examined singleton pregnancies. The hypothesis was that the performance of screening would be similar to that estimated from the original model 1 .
METHODS

Study design and participants
This was a prospective screening study for trisomies 21, 18 and 13 by a combination of maternal age, fetal NT, FHR and serum free β-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks' gestation in women booking for routine pregnancy care at King's College Hospital, London The eligibility criteria were singleton pregnancy with a live fetus at the 11-13-week scan. The Standards for Reporting Diagnostic accuracy studies (STARD) 9 were followed.
Test methods
The index test, or the test for which the accuracy was evaluated, was the previously reported algorithm for the first-trimester combined test which includes maternal age, fetal NT, FHR and serum free β-hCG and PAPP-A 1 (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, MA, USA). The index test was carried out prospectively in consecutive singleton pregnancies at 11 + 0 to 13 + 6 weeks' gestation; gestational age was determined from the measurement of fetal CRL 10 . The reference standard, or best available method for establishing the presence of the target condition, was prenatal fetal karyotype by chorionic villus sampling or amniocentesis and postnatal karyotype from neonatal blood; absence of the target condition was established by either prenatal karyotyping or clinical examination of a phenotypically normal neonate.
Statistical analysis
The previously described algorithm 1 was used to calculate the patient-specific risk of trisomies 21, 18 and 13 in each patient. Two prespecified analyses were then carried out: (1) the observed screen-positive rate and standardized rates according to the maternal-age distribution in England and Wales in 2011 11 , at risk cut-offs from 1 in 2 to 1 in 1000, of fetuses with abnormal and normal karyotype with screening by a combination of maternal age, fetal NT, serum free β-hCG and PAPP-A, with and without FHR; (2) the observed number and percentage of fetuses with each fetal karyotype, according to estimated risk derived from screening by a combination of maternal age, fetal NT, serum free β-hCG and PAPP-A, with and without FHR. The statistical software package R was used for data analyses 12 .
RESULTS
Participants
During the study period, we examined 115 838 singleton pregnancies. We excluded 6856 (5.9%) cases because they had missing outcome data (n = 5150) or fetal karyotype was unknown and the pregnancy resulted in termination, miscarriage or stillbirth (n = 1706).
In the study population of 108 982 pregnancies, 108 112 (99.2%) had normal fetal karyotype or birth of a phenotypically normal neonate and 870 (0.8%) had abnormal fetal karyotype, including trisomy 21 (n = 432), trisomy 18 (n = 166), trisomy 13 (n = 56), monosomy X (n = 63), triploidy (n = 35) or other aneuploidy (n = 118, i.e. sex chromosome aneuploidies (n = 15), deletions or duplications (n = 68), mosaic sex aneuploidies (n = 11), mosaic deletions or duplications (n = 6) and mosaic trisomies of chromosomes 2, 4, 8, 9, 13, 16, 21 or 22 (n = 18)). Baseline demographic and clinical characteristics of participants are shown in Table 1 .
Test results
The screen-positive rate, with 95% CIs, of fetuses with abnormal or normal karyotype on screening with the previously reported algorithm 1 is shown in Table 2 . At a risk cut-off of 1 in 100 for trisomy 21, 18 or 13, at the gestational age of screening, the observed FPR was 4.6% and the DR was 92%, 96% and 93% for trisomies 21, 18 and 13, respectively. At the same risk cut-off, 98% of cases of monosomy X, 97% of triploidies and 55% of other chromosomal abnormalities were detected. Inclusion of FHR in combined screening improved the DR of trisomy 13, especially at risk cut-offs > 1 in 50, but had no substantial effect on the DR of other chromosomal abnormalities. The risk cut-off of 1 in 100 for trisomy 21 at the gestational age of screening corresponds to a risk of 1 in 150 at term, which is the cut-off recommended by the UK National Screening Committee to define the high-risk group that should be offered invasive testing or further screening by cell-free (cf) DNA testing.
The screen-positive rates standardized according to the maternal-age distribution in England and Wales in 2011 are shown in Table 3 . At a risk cut-off of 1 in 100, the FPR was about 4%, the DR of trisomy 21 was 90%, of trisomy 18 was 97% and of trisomy 13 was 92%; the respective values for risk cut-off of 1 in 10 were 0.6%, 73%, 91% and 85% and the respective values for risk cut-off of 1 in 1000 were 20%, 98%, 99% and 96%. These rates are comparable with those predicted previously using the algorithm 1 . The DR and screen-positive rates for each trisomy are shown in Figure 1 . Inclusion of FHR improves 
Data are given as median (interquartile range) or n (%). *Significant difference compared with normal group: P < 0.05. APS, antiphospholipid syndrome; BMI, body mass index; GA, gestational age; IVF, in-vitro fertilization; SLE, systemic lupus erythematosus. (4) 20 (7) 30 (11) 40 (15) 50 (18) 60 ( ) and without ( ) fetal heart rate data, in population with maternal-age distribution of that in England and Wales in 2011 for trisomies 21 (a), 18 (b) and 13 (c). Circles illustrate DR and SPR at risk cut-offs of 1 in 10, 1 in 100 and 1 in 1000. Numbers in brackets on y-axis are number of trisomy cases in population of 100 000 pregnancies at time of screening. At risk cut-off of 1 in 1000, SPR is about 20% and DRs are 98%, 99% and 96% for trisomies 21, 18 and 13, respectively. the performance of screening for trisomy 13, but not trisomies 21 or 18. Improvement in the DR of trisomy 21 from 96% to 98%, 99% and 99.5% would necessitate an increase in screen-positive rate from about 13% (risk cut-off 1 in 500) to 20% (risk cut-off 1 in 1000), 40% (risk cut-off 1 in 3500) and 54% (risk cut-off 1 in 6500), respectively.
The observed number and percentage, with 95% CIs, of fetuses in each fetal karyotype group according to estimated risk for trisomies 21, 18 or 13 derived from firsttrimester combined screening are shown in Table 4 and illustrated in Figure 2 . There was a tendency for the risks to be overestimated, but the 95% CIs for each observed prevalence of trisomies were within the estimated risks. Table 2 Observed screen-positive rate of fetuses with abnormal or normal karyotype in screening by a combination of maternal age, fetal nuchal translucency thickness, serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A, with and without fetal heart rate (FHR) data, at 11-13 weeks' gestation All pregnancies (n = 108 982)
Risk cut-off The observed and standardized rates for screening according to the UK National Screening Committee, in which the risk cut-offs refer to risks at term rather than at the time of first-trimester screening, are given in Tables S1 and S2 .
DISCUSSION
Main findings
The findings of this large prospective validation study demonstrate that the performance of first-trimester screening for trisomies 21, 18 and 13 by the combined test is similar to that estimated from the original model 1 . At a risk cut-off of 1 in 100 at the time of first-trimester screening, the DR of each of the three trisomies was ≥ 90% at a FPR of 4%. At this risk cut-off, nearly all cases of monosomy X and triploidy, and more than half of all other chromosomal abnormalities, can also be detected. Inclusion of FHR in the combined test, which requires only a few seconds to measure at no additional cost, improves the DR of trisomy 13.
There was a tendency for overestimation of the risks for trisomies 21, 18 and 13 by the combined test, but the 95% CIs for each observed prevalence of trisomies was within the estimated risks. One possible explanation for such overestimation of risks is under-ascertainment of these trisomies; in the 1706 pregnancies excluded from the study because of termination, miscarriage or stillbirth without fetal karyotyping, the rate of chromosomal abnormality is likely to be overrepresented 13 .
Study limitations
The main limitation of our screening study relates to ascertainment of pregnancy outcome. In the case of trisomies 21, 18 and 13, the lack of karyotyping in some cases resulting in termination, miscarriage and stillbirth may have underestimated the performance of screening because these abnormalities are associated with a higher rate of intrauterine lethality than are euploid fetuses, especially in the screen-positive group. Unlike with trisomies 21, 18 and 13, most neonates with sex chromosome aneuploidy and those in the heterogeneous group classified as having other chromosomal abnormality are often phenotypically normal 14 . Consequently, studies that do not involve karyotyping of the whole population will inevitably underestimate the true prevalence of these abnormalities and overestimate the potential sensitivity of a prenatal screening test. For example, we reported previously that an erroneous conclusion could be reached, that screening for trisomies 21, 18 and 13 by the combined test and carrying out an invasive test for those with a risk ≥ 1:100 could identify 67% of fetuses with 47,XXY, 47,XYY or 47,XXX, but the true sensitivity may be as low as 8% 14 .
Implications for practice
The combined test provides effective screening for trisomies 21, 18 and 13 and helps identify a high proportion of other chromosomal abnormalities, at a FPR of 4%. In the last 5 years, a major improvement in screening for trisomies has been achieved through Table 4 Observed number of fetuses in each karyotype group according to estimated risk derived from screening by a combination of maternal age, fetal nuchal translucency thickness, serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A, with or without fetal heart rate (FHR) data, at 11-13 weeks' gestation Risk category
All pregnancies (n = 108 982) analysis of cfDNA in maternal blood. A meta-analysis of clinical validation and implementation studies reported that, with cfDNA testing, the DR for trisomies 21, 18 and 13 were 99%, 96% and 91%, respectively, at an overall FPR of 0.35% 15 . Universal screening by cfDNA testing as an alternative to the combined test would improve the DR of trisomy 21 and reduce the rate of invasive testing. However, such policy would be expensive and ignores the other benefits of the combined test, including early detection of many major fetal defects, diagnosis of multiple pregnancy and its chorionicity, detection of chromosomal defects other than trisomies 21, 18 and 13 and early prediction of pregnancy complications, such as pre-eclampsia, with the potential of prevention through prophylactic pharmacological interventions.
The alternative to universal screening by the cfDNA test is a strategy of cfDNA testing contingent on the results of first-line screening by the combined test. This approach retains the major advantages of cfDNA testing in increasing DR and decreasing FPR, but at considerably lower cost than offering cfDNA testing to the whole population. As demonstrated in this study, at a risk cut-off of 1 in 500 from the combined test, about 13% of the population would be selected and would contain 96% of cases of trisomy 21. If the cut-off was increased to 1 in 1000, about 20% of the population would be selected and would contain 98% of cases of trisomy 21. Further improvement in the DR of trisomy 21 to 99% would necessitate offering cfDNA testing to 40% of the population.
A preferred third strategy is to offer invasive testing to pregnancies with a very high risk from the combined test of ≥ 1 in 10 and reserve cfDNA testing for an intermediate-risk group with a risk of 1 in 11 to 1 in 500 or 1 in 1000. The very high-risk group comprising < 1% of the population would contain about 80% of cases with trisomies 21, 18 or 13, as well as > 90% of cases of monosomy X, > 85% of triploidy and > 30% of other chromosomal abnormality.
